|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Helicobacter pylori and extragastric diseases: A review显示文摘Helicobacter pylori(H. pylori) infection is very common and affects approximately half of the world population. It causes gastric diseases, but some authors have reported an association of H. pylori infection with other systemic manifestations beginning in 1994. The list of potential effects of H. pylori outside the stomach includes a number of extragastric manifestations and we focused on neurological, dermatological, hematologic, ocular, cardiovascular, metabolic, allergic, and hepatobiliary diseases. This review discusses these important reported manifestations that are not related to the gastrointestinal tract. | Antonietta Gerarda Gravina Rocco Maurizio Zagari Cristiana De Musis Lorenzo Romano Carmelina Loguercio Marco Romano | 2018 | World Journal of Gastroenterology2018，24，29： | 90 |
| 2 | Silybin and the liver: From basic research to clinical practice显示文摘Herbal products are increasingly used, mainly in chronic liver disease. Extracts of milk thistle, Silymarin and silybin, are the most prescribed natural compounds, with different indications, but with no definitive results in terms of clinical efficacy. This review analyzes the available studies on the effects of the purified product silybin, both as a free and a conjugated molecule, on liver cells or on experimentally induced liver damage, and in patients with liver disease. We searched PUBMED for articles pertaining to the in vitro and in vivo effects of silybin, its antifibrotic, anti-inflammatory, and antioxidant properties, as well as its metabolic effects, combined with the authors’ own knowledge of the literature. Results indicate that the bioavailability of silybin phytosome is higher than that of silymarin and is less influenced by liver damage; silybin does not show significant interactions with other drugs and at doses < 10 g/d has no significant side effects. Experimental studies have clearly demonstrated the antifibrotic, antioxidant and metabolic effects of silybin; previous human studies were insufficient for confirming the clinical efficacy in chronic liver disease, while ongoing clinical trials are promising. On the basis of literature data, silybin seems a promising drug for chronic liver disease. | Carmela Loguercio Davide Festi | 2011 | World Journal of Gastroenterology2011，17，18： | 26 |
| 3 | Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease显示文摘Non-alcoholic fatty liver disease(NAFLD)has become the most common liver disorder in Western countries and is increasingly being recognized in developing nations.Fatty liver disease encompasses a spectrum of hepatic pathology,ranging from simple steatosis to non-alcoholic steatohepatitis,cirrhosis,hepatocellular carcinoma and end-stage liver disease.Moreover,NAFLD is often associated with other metabolic conditions,such as diabetes mellitus type 2,dyslipidemia and visceral obesity.The most recent guidelines suggest the management and treatment of patients with NAFLD considering both the liver disease and the associated metabolic co-morbidities.Diet and physical exercise are considered the first line of treatment for patients with NAFLD,but their results on therapeutic efficacy are often contrasting.Behavior therapy is necessary most of the time to achieve a sufficient result.Pharmacological therapy includes a wide variety of classes of molecules with different therapeutic targets and,often,little evidence supporting the real efficacy.Despite the abundance of clinical trials,NAFLD therapy remains a challenge for the scientific community,and there are no licensed therapies for NAFLD.Urgently,new pharmacological approaches are needed.Here,we will focus on the challenges facing actual therapeutic strategies and the most recent investigated molecules. | Alessandro Federico Claudio Zulli Ilario de Sio Anna Del Prete Marcello Dallio Mario Masarone Carmela Loguercio | 2014 | World Journal of Gastroenterology2014，20，45： | 10 |
| 4 | Eradication of Helicobacter pylori infection:Which regimen first?显示文摘Helicobacter pylori(H.pylori)is a well-known human pathogen that plays an essential role in the pathogenesis of chronic gastritis,peptic ulcer disease,and gastric malignancies.Although H.pylori is susceptible to several antimicrobials,this infection has proven challenging to cure because of the increasing prevalence of bacterial strains that are resistant to the most commonly used antimicrobials,particularly clarithromycin.An effective(i.e.,>90%)first-line therapy is mandatory for avoiding supplementary treatments and testing,and more importantly for preventing the development of secondary resistance.This study reviews the recent literature on first-line therapies forH.pylori.The eradication rates following standard triple therapy(a proton pump inhibitor plus amoxicillin and clarithromycin)for H.pylori infection are declining worldwide.Several first-line strategies have been proposed to increase the eradication rate,including extending the treatment duration to 14 d,the use of a four-drug regimen(bismuth-containing quadruple,sequential,and concomitant treatments),and the use of novel antibiotics,such as fluoroquinolones.However,the ef5ficacy of these regimens is controversial.A first-line eradication regimen should be based on what works best in a defined geographical area and must take into account the prevalence of antimicrobial resistance in that region. | Alessandro Federico Antonietta Gerarda Gravina Agnese Miranda Carmela Loguercio Marco Romano | 2014 | World Journal of Gastroenterology2014，20，3： | 6 |
| 5 | Non Alcoholic Fatty Liver: Epidemiology and Natural History显示文摘 | Mario Masarone Alessandro Federico Ludovico Abenavoli Carmela Loguercio Marcello Persico | 2014 | Reviews on Recent Clinical Trials2014，，3： | 4 |
| 6 | Efficacy of 5-Day Levofloxacin-Containing Concomitant Therapy in Eradication of Helicobacter pylori Infection显示文摘 | Alessandro Federico Gerardo Nardone Antonietta G. Gravina Maria Rosaria Iovene Agnese Miranda Debora Compare Paola A. Pilloni Alba Rocco Luigi Ricciardiello Riccardo Marmo Carmelina Loguercio Marco Romano | 2012 | Gastroenterology2012，，1： | 3 |
| 7 | Beneficial Effects of a Probiotic VSL#3 on Parameters of Liver Dysfunction in Chronic Liver Diseases显示文摘 | Carmela Loguercio Alessandro Federico Concetta Tuccillo Fulvia Terracciano Mauro Valeriano D?Auria Claudio De Simone Camillo Del Vecchio Blanco | 2005 | Journal of Clinical Gastroenterology2005，，6： | 2 |
| 8 | Safety and efficacy of sorafenib in patients with advanced hepatocellularcarcinoma and Child-Pugh A or B cirrhosis显示文摘 | Alessandro Federico Michele Orditura Gaetano Cotticelli Ilario De Sio Marco Romano Antonietta Gravina Marcello Dallio Alessio Fabozzi Fortunato Ciardiello Carmela Loguercio Ferdinando De Vita | 2015 | Oncology Letters2015，，4： | 2 |
| 9 | Beneficial Effects of a Probiotic VSL#3 on Parameters of Liver Dysfunction in Chronic Liver Diseases显示文摘 | Carmela Loguercio Alessandro Federico Concetta Tuccillo Fulvia Terracciano Mauro Valeriano D?Auria Claudio De Simone Camillo Del Vecchio Blanco | 2005 | Journal of Clinical Gastroenterology2005，，6： | 2 |
| 10 | Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease显示文摘 | P. Loria L.E. Adinolfi S. Bellentani E. Bugianesi A. Grieco S. Fargion A. Gasbarrini C. Loguercio A. Lonardo G. Marchesini F. Marra M. Persico D. Prati G. Svegliati- Baroni | 2010 | Digestive and Liver Disease2010，，4： | 2 |
| 11 | The effect of a silybin-vitamin e-phospholipid complex on nonalcoholic fatty liver disease: a pilot study显示文摘 | Loguercio C Federieo A Trappoliere M | 2007 | Dig Dis Sci2007，52，9： | 1 |
| 12 | Oxidative stress in viral and alcoholic hepatitis显示文摘 | Loguercio C Federico A | 2003 | Free Radic Biol Med2003，34，1： | 1 |
| 13 | A 24-month follow-up of flowable resin composite as an intermediate layer in non-carious cervical lesions显示文摘 | Reis A Loguercio AD | 2006 | Oper Dent2006，31，5： | 1 |
| 14 | Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic li- ver diseases显示文摘 | Loguercio C Federico A Tuccillo C et ol | 2005 | J Clin Gastroenterol2005，39，6： | 1 |
| 15 | Non-alcoholic fatty liver disease in an area of southern Italy: main clinical, histological, and pathpphysiological aspects显示文摘 | Loguercio C De Girolamo V Desiol | 2001 | Hepatol2001，35，5： | 1 |
| 16 | Alteration of erythrocyte glutathione,cysteine and glutathione synthetase in alcoholic and on-alcoholic cirrhosis 显示文摘 | Loguercio C Del VC Cohorti G | 1992 | Scand J Clin Lab Invest1992，52，： | 1 |
| 17 | Re -attachment of anterior fractured teeth : fracture strength using different techniques 显示文摘 | Reis A Francci C Loguercio AD | 2001 | Oper Dent2001，26，3： | 1 |
| 18 | Beneficial effects of a probiotie VSL 3 on parameters of liver dysfunction in chronic liver diseases显示文摘 | Loguercio C Federico A Tuccillo C | 2005 | J Clin Gastroenterol2005，39，6： | 1 |
| 19 | Influence of chlorhexidine digluconate concentration and application time on resin-dentin bond strength durability显示文摘 | Loguercio AD Stanislawczuk R Polli LG | 2009 | Eur J Oral Sci2009，117，5： | 1 |
| 20 | Liver failure in an obese middle-aged woman after biliointestinal bypass显示文摘Obesity is considered an emerging epidemic that is often associated with non-alcoholic fatty liver disease. Among the therapeutic options for morbid obesity, bariatric surgery plays an important role when conventional therapies fail. The effects of bariatric surgery on liver function and morphology are controversial in the literature. Liver failure has been reported after jejunoileal bypass(JIB), biliopancreatic diversion and gastric bypass. Biliointestinal bypass(BIB) is considered an effective procedure among recently introduced bariatric surgery techniques. It is a clinically safe, purely malabsorptive operation in which the blind intestinal loop of the JIB is anastomosed to the gallbladder, allowing a portion of bile to transit into excluded intestinal tract. BIB is the only procedure, to our knowledge, to have no liver side effects reported in the literature. We report the case of a young obese woman who developed liver failure 8 mo after BIB. She had a rapid weight loss(70 kg) with a reduction in body mass index of 41% from January to September 2012. Because of a severe hepatic decompensation, she was referred to a transplantation centre. We strongly believe that the most important pathogenetic mechanism involved in the development of liver injury is the rapid weight loss that produced a signif icant fatty liver inf iltration. | Dolores Sgambato Gaetano Cotticelli Ilario de Sio Annalisa Funaro Anna Del Prete Chiara de Sio Lorenzo Romano Alessandro Federico Antonietta Gravina Agnese Miranda Carmelina Loguercio Marco Romano | 2013 | World Journal of Clinical Cases2013，1，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员